Imdur 30mg Tablet (Isosorbide Mononitrate)

Description

Imdur 30mg Tablet (Isosorbide Mononitrate) — Complete Clinical and Patient Information Guide

Product Overview

Imdur 30mg Tablet (Isosorbide Mononitrate) contains Isosorbide Mononitrate 30mg SR as its active pharmaceutical ingredient, belonging to the organic nitrate — isosorbide mononitrate sustained-release for angina prophylaxis. It is clinically indicated for prophylaxis of stable angina pectoris. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Imdur 30mg is AstraZeneca’s originator sustained-release ISMN formulation — one of the most extensively studied and clinically validated long-acting nitrate preparations, providing once-daily morning angina prophylaxis with automatic overnight tolerance prevention.

About Imdur 30mg and Its Active Ingredient

Isosorbide Mononitrate 30mg SR is the pharmacologically active compound in Imdur 30mg, a well-established cardiovascular or therapeutic agent with a clinical evidence base developed across decades of research. All cardiovascular and hormonal pharmacotherapy requires physician supervision — drug interactions, contraindications, and dose optimisation decisions require professional medical assessment. Never start, change, or stop these medications without consulting your prescribing physician.

Mechanism of Action

Isosorbide mononitrate (ISMN) is an organic nitrate that undergoes enzymatic metabolism to release nitric oxide (NO) in vascular smooth muscle. NO activates guanylate cyclase, increasing cGMP, activating protein kinase G, and causing vasodilation — predominantly venodilation at standard doses (reducing preload) with coronary arterial dilation at higher doses. ISMN’s advantage over ISDN is 100% oral bioavailability (no hepatic first-pass conversion required, as ISMN is already the active form). Imdur is the AstraZeneca originator brand SR ISMN, one of the most established long-acting nitrate formulations globally.

Clinical Indications

Imdur 30mg Tablet (Isosorbide Mononitrate) is indicated for:

• Primary indication: prophylaxis of stable angina pectoris
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of therapy.

Dosage and Administration

Imdur 30mg SR once daily in the morning. Sustained-release formulation provides automatic overnight nitrate-free interval when taken in the morning — preventing nitrate tolerance. NEVER take at bedtime.

Who Should Use Imdur 30mg

Imdur 30mg is appropriate for patients confirmed by a qualified healthcare professional to have the conditions listed in the indications section, in whom this specific formulation is clinically appropriate following benefit-risk assessment with no absolute contraindications.

Contraindications

PDE5 inhibitors (sildenafil, tadalafil, vardenafil) — ABSOLUTE CONTRAINDICATION. Severe hypotension. Hypovolaemia.

Drug Interactions

PDE5 inhibitors: absolute contraindication — life-threatening hypotension. Antihypertensives: additive hypotension. Alcohol: additive hypotension.

A complete medication review is essential before initiating Imdur 30mg. Cardiovascular and hormonal drugs have numerous clinically significant interactions that can be dangerous if unidentified. Patients must inform all healthcare providers of their complete medication list.

Adverse Effects

Headache (very common, especially during first week). Flushing, dizziness, postural hypotension. Tolerance develops with continuous 24-hour exposure — prevented by morning-only dosing.

Special Population Considerations

Imdur is the AstraZeneca originator SR-ISMN brand. CRITICAL dosing instruction: always take in the morning, never at bedtime — the overnight nitrate-free interval from morning-only once-daily dosing is essential to prevent haemodynamic tolerance. If taken at bedtime, tolerance develops within 24–48 hours and the drug loses anti-anginal effectiveness.

Storage

Store Imdur 30mg at room temperature (15–25°C) away from direct sunlight, heat, and moisture. Keep in original packaging. Maintain out of reach of children. Do not use beyond expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop cardiovascular medications abruptly without medical advice.

Q: Why can I only take Imdur in the morning?
A: Continuous nitrate exposure causes tolerance — the vascular response to nitrate diminishes, reducing anti-anginal efficacy. The Imdur SR formulation releases drug over approximately 8–10 hours after a morning dose, providing active nitrate coverage during daytime activity while allowing an overnight nitrate-free period (approximately 8–12 hours). This daily nitrate-free window regenerates vascular sensitivity to nitrate before the next morning dose, maintaining sustained anti-anginal efficacy.

Evidence Base and Clinical Guidelines

The active ingredient in Imdur 30mg has been evaluated in landmark randomised controlled trials and is supported by international cardiovascular guidelines from the ESC, ACC/AHA, NICE, and national specialist bodies. Evidence-based cardiovascular pharmacotherapy has transformed outcomes for hypertension, angina, heart failure, and arrhythmia management. GMP-compliant manufacturing ensures consistent product quality and safety.

Cardiovascular Disease Management Context

Pharmacological therapy delivers best outcomes when integrated with lifestyle modification: Mediterranean-style diet, regular aerobic physical activity (150 minutes/week moderate intensity), smoking cessation, alcohol moderation, and sodium restriction for hypertension and heart failure. The combination of optimal pharmacotherapy and sustained lifestyle change produces cardiovascular risk reduction far exceeding either approach alone. Regular follow-up monitoring — blood pressure recording, ECG, renal function and electrolytes — is essential to optimise therapy and detect adverse effects early.

Fixed-dose combination antihypertensive tablets — such as many products in this range — significantly improve treatment adherence, which is the single most common reason for inadequate blood pressure control in treated hypertensive patients. Multiple studies demonstrate that every 10mmHg sustained reduction in systolic blood pressure reduces major cardiovascular event risk by approximately 20%, providing strong motivation for achieving and maintaining blood pressure targets.

Patient Counselling Key Points

• Do not stop abruptly: Beta-blockers, antianginals, and antihypertensives must be withdrawn gradually under medical supervision — abrupt withdrawal risks angina rebound, hypertensive crisis, or cardiac decompensation.
• Monitor blood pressure: Home blood pressure monitoring at the same time daily provides valuable data for dose optimisation — target below 130/80 mmHg in most guidelines for hypertensive patients with cardiovascular disease.
• Carry medication list: All patients on cardiovascular medications should carry a complete medication list for surgical, dental, and emergency care encounters where drug interactions are critical.

Cardiovascular Disease Management Principles

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, responsible for approximately 18 million deaths annually. Hypertension alone affects 1.28 billion adults globally — yet only 21% achieve adequate blood pressure control. The gap between evidence-based pharmacotherapy and real-world practice represents the greatest opportunity for cardiovascular risk reduction: consistently achieving guideline-recommended blood pressure targets, lipid goals, and cardiac function optimisation through appropriate, adherent pharmacotherapy has the potential to prevent hundreds of thousands of cardiovascular events annually.

Modern antihypertensive management has evolved substantially — from the early era of single-drug therapy to the current paradigm of early combination therapy targeting multiple pathophysiological mechanisms simultaneously. Multiple large randomised controlled trials and their meta-analyses demonstrate that combination antihypertensive therapy achieves blood pressure targets more effectively than monotherapy titration, with better cardiovascular outcomes. The ACCOMPLISH trial demonstrated CCB+ACE-I superiority over diuretic+ACE-I for cardiovascular events; ONTARGET established ARB equivalence to ACE-I; MERIT-HF, COPERNICUS, CIBIS-II, and EMPHASIS-HF established beta-blocker and MRA therapy for HFrEF. This robust evidence base is incorporated into ESC, ACC/AHA, and NICE guidelines that inform contemporary prescribing decisions.

Fixed-Dose Combination Therapy: Adherence and Outcomes

Non-adherence to antihypertensive therapy is the single most common reason for inadequate blood pressure control in treated patients — affecting approximately 50% of patients within the first year of treatment. Fixed-dose combinations (FDCs) address this critical problem by reducing pill burden, simplifying regimens, and improving convenience. Multiple meta-analyses confirm that FDC antihypertensive therapy significantly improves adherence compared to equivalent separate tablets, translating to better blood pressure control and improved cardiovascular outcomes.

The products in this range — spanning beta-blockers with CCBs, ARBs with CCBs and diuretics, triple combinations, and specialised anti-anginal agents — reflect contemporary evidence-based combination therapy strategies. Selection among these options requires individual patient assessment integrating blood pressure severity, comorbidities (diabetes, CKD, heart failure, AF), tolerability factors, and concurrent medications.

Evidence Base and Quality Standards

The active ingredients in this product have been evaluated in landmark randomised controlled trials forming the foundation of evidence-based cardiovascular medicine. Major international guidelines from the European Society of Cardiology (ESC/ESH), American College of Cardiology/American Heart Association (ACC/AHA), and National Institute for Health and Care Excellence (NICE) support their use in evidence-based treatment algorithms. GMP-compliant manufacturing ensures consistent product quality, identity, strength, and safety across all manufactured batches. Patients should obtain prescription cardiovascular medications only through licensed pharmacies with valid prescriptions to ensure receipt of authentic, quality-assured products.

Blood Pressure Targets and Monitoring

Current major cardiovascular guidelines (ESC/ESH 2023, ACC/AHA 2017) recommend the following blood pressure targets for hypertensive patients: general adult population with uncomplicated hypertension, target below 130/80 mmHg; patients aged ≥65 years, target 130–139/70–79 mmHg (avoiding over-treatment which may paradoxically increase risk through J-curve phenomena); patients with CKD and proteinuria, target below 130/80 mmHg; patients with coronary artery disease and stable angina, target 130/80 mmHg or lower; patients with diabetes mellitus, target below 130/80 mmHg.

Home blood pressure monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are recommended over office BP measurements alone for treatment decisions — office measurements overestimate true BP (white coat hypertension) in approximately 15–30% of patients and underestimate it (masked hypertension) in others. ABPM or HBPM provides more accurate cardiovascular risk assessment and better treatment optimisation.

Patient Counselling Summary

Key points for all patients on antihypertensive and cardiovascular medications: Take medications at the same time daily for consistent drug levels. Never skip doses — cardiovascular medications require consistent daily use for their full protective benefit. Never stop medications abruptly — particularly beta-blockers (rebound angina/hypertension risk) and antianginal drugs. Monitor blood pressure at home at the same time each day in a relaxed, seated position after 5 minutes rest. Report side effects promptly — many can be managed with dose adjustment or substitution rather than discontinuation. Maintain lifestyle modifications: salt restriction (below 6g/day), DASH or Mediterranean diet, regular moderate-intensity aerobic exercise (150 minutes/week), smoking cessation, and alcohol moderation. Attend all scheduled follow-up appointments for blood pressure recording, ECG, and biochemical monitoring as indicated.

Drug-Drug Interaction Awareness

Cardiovascular patients are among the most heavily medicated patient populations — polypharmacy is the norm rather than the exception. The average patient with established cardiovascular disease takes 5–10 prescription medications daily, creating a complex matrix of potential drug-drug interactions that requires active management. Key interaction categories of particular importance in cardiovascular medicine include: CYP3A4 substrate CCBs (amlodipine, nifedipine, diltiazem, verapamil) with azole antifungals, macrolide antibiotics, and HIV protease inhibitors; beta-blockers with verapamil, diltiazem, and antiarrhythmics; antiplatelet agents with anticoagulants; and organic nitrates with PDE5 inhibitors (absolute contraindication of critical safety importance).

All patients on cardiovascular medications should receive a formal medication review at each GP or specialist visit. An updated and complete medication list should be maintained and shared with all healthcare providers, including dentists, surgeons, and emergency physicians. Many drug interactions can be safely managed through dose adjustment, timing modification, or alternative agent selection — but only when proactively identified before harm occurs.

Geriatric Cardiovascular Pharmacology

Elderly patients (age ≥65) represent the majority of cardiovascular drug users and present unique pharmacological challenges: reduced renal and hepatic clearance prolongs drug half-lives and increases plasma levels; increased body fat and decreased lean mass alters volume of distribution; reduced plasma protein binding increases free drug fractions; and reduced homeostatic reserve (baroreceptor sensitivity, autonomic function) amplifies drug effects on blood pressure and heart rate. Starting doses in elderly patients should typically be 50% of standard adult doses with slower titration intervals. Postural hypotension risk is particularly important — antihypertensive drugs causing orthostatic BP drops predispose elderly patients to falls and their devastating consequences (hip fractures, intracranial haemorrhage). Target blood pressure ranges in elderly patients are generally less aggressive than in younger patients to avoid over-treatment.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It does not replace professional medical advice from a qualified physician, cardiologist, endocrinologist, gynaecologist, or pharmacist. Drug therapy decisions must be individualised. Self-diagnosis and self-treatment of cardiovascular, hormonal, and parasitic conditions can be dangerous. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.